Jun 15, 2022 / 01:30PM GMT
Jason Butler - JMP Securities LLC - Analyst
Let me say again, thank you, everybody, for being here in person at the JMP Securities 2022 life sciences conference. Next company we have with us is Syros Pharmaceuticals. We have Nancy Simonian, company's CEO. Nancy, welcome.
Nancy Simonian - Syros Pharmaceuticals, Inc. - President & CEO
Thank you.
Jason Butler - JMP Securities LLC - Analyst
So again, another busy year for you. So maybe I'd just offer it to you to give a quick high-level intro of Syros, your lead programs, and we'll jump in from there.
Nancy Simonian - Syros Pharmaceuticals, Inc. - President & CEO
Yeah. It's an incredibly exciting time at the company. We have three programs in clinical development. Our most advanced, tamibarotene, is at a Phase 3 registration-enabling study in high-risk MDS. We expect data from that study end of 2023, early 2024. We also have tamibarotene being studied in AML, and we will have data later this year from a safety lead-in
Syros Pharmaceuticals Inc at JMP Securities Life Sciences Conference Transcript
Jun 15, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers